Treatment of residual breast cancer
- Authors: Ereschenko S.S1, Semiglazov V.F1, Krivorotko P.V1, Dashyan G.A1, Smirnova V.O1, Komyakhov A.V1, Gigolaeva L.P1, Zhiltsova E.K1
-
Affiliations:
- N.N. Petrov National Medical Research Center for Oncology
- Issue: Vol 27, No 7 (2020)
- Pages: 46-52
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312716
- DOI: https://doi.org/10.18565/pharmateca.2020.7.46-52
- ID: 312716
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
S. S Ereschenko
N.N. Petrov National Medical Research Center for OncologySt. Petersburg, Russia
V. F Semiglazov
N.N. Petrov National Medical Research Center for Oncology
Email: vsemiglazov@mail.ru
Dr. Sci. (Med.), Corr. Member of RAS, Professor, Head of the Scientific Department, Chief Researcher at the Scientific Department of Breast Tumors 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation
P. V Krivorotko
N.N. Petrov National Medical Research Center for OncologySt. Petersburg, Russia
G. A Dashyan
N.N. Petrov National Medical Research Center for OncologySt. Petersburg, Russia
V. O Smirnova
N.N. Petrov National Medical Research Center for OncologySt. Petersburg, Russia
A. V Komyakhov
N.N. Petrov National Medical Research Center for OncologySt. Petersburg, Russia
L. P Gigolaeva
N.N. Petrov National Medical Research Center for OncologySt. Petersburg, Russia
E. K Zhiltsova
N.N. Petrov National Medical Research Center for OncologySt. Petersburg, Russia
References
- Семиглазов В.В., Криворотько П.В., Семиглазов В.Ф. и др. Международные рекомендации по лечение раннего рака молочной железы: руководство для врачей / Под ред. В.Ф. Семиглазова. М.: МК, 2020.232 с
- Mauri D, Pavlidis N., loannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188-194. doi: 10.1093/jnci/dji021.
- Semiglazov V.F., Topuzov E.E., Bavli J.L., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994;5:591-95. Doi: 10.1093/ oxfordjournals.annonc.a058929.
- Cortazar P, Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72. Doi: 10.1016/ S0140-6736(13)62422-8.
- Семиглазов В.Ф., Криворотько П.В., Семиглазова Т.Ю. и др. Рекомендации по лечению рака молочной железы. М.: Мегаполис, 2017. 168 с.
- Curigliano G., Burstein H.J., Winer E.P, et al. De-escalating and Escalating Treatments for Early-Stage Breast Cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncology. 2017,28:1700-12. doi: 10.1093/annonc/mdx308.
- Cardoso F, Kyriakides S., Ohno S., et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2019,30:1194-220.
- Robson M., Im S.A., Senkus E., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-33. Doi: 10.1056/ NEJMoa1706450.
- Litton J.K., Rugo H.S., Ettl J., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-63. Doi: 10.1056/ NEJMoa1802905.
- Miller K., Tong Y., Jones D.R., et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of Hoosier Oncology Group BRE09-146. J Clin Oncol. 2015;33(Suppl. 15):abstract 1082. doi: 10.1200/jco.2015.33.15_suppl.1082.
- Dieras V., Miles D., Verma S., et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:732-42. Doi: 10.1016/ S1470-2045(17)30312-1.
- Gunter von Minckwitz P.C. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72. doi: 10.1016/S0140-6736(13)62422-8.
- Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-doi: 10.1056/NEJMoa1612645.
- von Minckwitz G., Huang C.S., Mano M.S., et al. Trastuzumab emtansine for residual invasive HER2-Positive breast cancer. N Engl J Med. Epub ahead of print 5 December 2018. Doi: 10.1056/ NEJMoa1814017.
- Symmans W.F., Wei C., Gould R., et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35:1049-doi: 10.1200/JCO.2015.63.1010.
- Law M.E., Corsino P.E., Narayan S., et al. Cyclindependent kinase inhibitors as anticancer therapeutics. Mol Pharmacol. 2015;88:846-52. doi: 10.1124/mol.115.099325.
- Finn R.S., Crown J.P, Lang I., et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35. doi: 10.1016/S1470-2045(14)71159-3.
- Sledge G.W., Toi M., Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875-84. doi: 10.1200/JCO.2017.73.7585.
- Slamon D.J., Neven P, Chia S., et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor Receptor 2-Negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-72. Doi: 10.1200/ JCO.2018.78.9909.
- Semiglazov V.F, Semiglazov K.K, Dashyan G.A., et al. Phaze II randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer. 2007;110(2):244-54. doi: 10.1002/cncr.22789.
- Sinn H.P., Schneeweiss A., Keller M., et al. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017;17:124. doi: 10.1186/s12885-017-3111-1.
- Семиглазов В.Ф., Криворотько П.В., Семиглазов В.В. и др. Иммунология рака молочной железы. М.: СИМК, 2019. [Semiglazov V.F, Krivorotko P.V., Semiglazov K.K, et al. Immunology of breast cancer. M.: SIMK, 2019. (In Russ.)].
- Hamy A., Pierga J., Sabalia A., et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. 2017;28(9):2233-40.
- Salgado R., Denkert C., Demaria S., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer recommendations by an International TILs Working Group 2014. Ann Oncol. 201;26(2):259-71.
- Pohlmann P.R., Diamond J.R., Hamilton E.P, et al. Atezolizumab+ nab-paclitaxel in metastatic triple-negative breast cancer: 2-year update from a phase Ib trial. Poster presented at 2018 American Association for Cancer Research Annual Meeting; April Meeting; April 14-18, 2018; Chicago, Illinois.
- Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed be adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial); a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375;377-84.
- Miles D, Gligorov J, Andre F, et al. Primary results from Impasion 131, double-blind placebo-controlled randomized phase 3 trial of paclitaxel ± atezolizumab as first - line therapy for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC). SABCS. 2019;Dec 12;0-5.
Supplementary files
![](/img/style/loading.gif)